Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cas... (perating earnings growth. At the same ti...)

Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend

Date:10/23/2007

perating earnings growth. At the same time, we continue to believe Aflac Japan is building sales momentum, and we remain encouraged about our sales outlook for the balance of this year and into 2008.

"Aflac U.S. is also performing very well this year. Our persistency has been steady and our benefit and expense ratios and profit margin have been in line with our expectations. Our sales results have also been strong during the first nine months of the year. And we believe our focus on training and enhancing the capabilities of our distribution will continue to enhance our future sales activities.

"I remain confident that we will achieve our primary financial goal for 2007 of increasing operating earnings per diluted share by 15% to 16%, or $3.28 to $3.31, excluding foreign currency translation. Assuming the yen averages 115 to 120 to the dollar for the remainder of the year, we would expect to report operating earnings of $3.24 to $3.28 per diluted share for the full year. For the fourth quarter of 2007, we expect operating earnings will be in the range of $.75 to $.79 per diluted share. As we look to 2008, I believe we are also well-positioned to achieve our objective of increasing operating earnings per diluted share by 13% to 15%, before the impact of the yen."

For more than 50 years, Aflac products have given policyholders the opportunity to direct cash where it is needed most when a life-interrupting medical event causes financial challenges. Aflac is the number one provider of guaranteed-renewable insurance in the United States and the number one insurance company in terms of individual insurance policies in force in Japan. Our insurance products provide protection to more than 40 million people worldwide. Aflac has been included in Fortune magazine's listing of America's Most Admired Companies for seven consecutive years and in Fortune magazine's list of the 100 Best Companies to Work For in America for nine consecutive years. Aflac has also b
'/>"/>

SOURCE Aflac Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care

Post Your Comments:

(Date:6/18/2013)... Petersburg, FL (PRWEB) June 19, 2013 ... 5 minutes a day could boost your health and ... Kathy Heshelow, founder of Sublime Beauty®. "It is called ... practiced for centuries but became a lost art. Now, ... celebrities know about Skin Brushing, and so do certain ...

(Date:6/18/2013)... June 19, 2013 An apple a ... Christina Beauregard was diagnosed with breast cancer, she chose ... new book, “I Gave Myself Cancer, I Can Take ... by Balboa Press), Beauregard explains how changing her physical, ... "Sick people have been made to feel fearful when ...

(Date:6/18/2013)... June 18, 2013 Daily Gossip Magazine has ... reviews and useful articles. , The magazine has decided ... to a new anabolic recipe every week . ... is the perfect guide for readers who are looking to ... at Daily Gossip reveals that anabolic food is almost entirely ...

(Date:6/18/2013)... 19, 2013 The Drug Delivery Partnering ... access to the drug delivery partnering deals and agreements ... , The report provides a detailed understanding and analysis ... deals. The majority of deals are discovery or development ... option right to license the license drug delivery technology. ...

(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...

Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2 Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2 Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4 Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2

[0] The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty®[0] Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method [0] Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders [0] New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz [0] Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting

... Inc. (NYSE:,CVD), a leading provider of drug development ... Merck & Co., Inc.,s Outstanding,Strategic Collaboration Award., ... 12 suppliers who,were selected from thousands of Merck ... performance; contributions towards the Key,Business Result (KBR) for ...

... GXDX ), a specialized laboratory services provider, today reported,revenues ... and $50.1 million,for the first half of 2008, as ... the respective periods in 2007. Stated revenue for the,first ... changes in,accounting estimates relating to prior periods., "Our ...

... mortality 25% in chronic kidney cases , , THURSDAY, July ... -- a routinely measured marker of bone disease -- ... receiving dialysis for chronic kidney disease, say U.S. researchers. ... patients during a three-year period. It found that patients ...

... COMMERCIAL LAUNCH OF HEARTMATE II(R) ... FOR BRIDGE-TO-TRANSPLANTATION, PLEASANTON, Calif., July 31 ... support therapies to save, support and restore failing hearts,today said that ... in the same period a year ago., Revenues for the ...

... she had hearing loss at 30, when she volunteered to ... sounds she could not hear. , Her husband Larry, ... history. Her mother, grandfather and great-grandfather had severe hearing loss ... before he reached school age. , The hearing loss ...

... 31 HealthSouth,Corporation (NYSE: HLS ) ... owned,subsidiaries, its previously announced purchase of The ... rehabilitation hospital in,Vineland, NJ, from The Mediplex/Cumberland ... South Jersey, under the outstanding,leadership of Dr. ...

Covance Recognized for Outstanding Performance by Merck & Co., Inc.Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 Bone Disease Test Shows Death Risk for Dialysis Patients Thoratec Reports 44 Percent Increase in Second Quarter Revenues;Inherited form of hearing loss stems from gene mutation HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital

(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...

(Date:6/18/2013)... -- Today, Wall Street Reports announced new research ... Health Management Associates Inc. (NYSE: HMA ), IDEXX ... (NASDAQ: ISIS ), and Trius Therapeutics Inc. (NASDAQ: ... - including full price targets, industry analysis and analyst ratings ... Research Report On June 7, 2013, Gilead Sciences ...

(Date:6/18/2013)... , June 18, 2013 Apama Medical, ... the development of next-generation atrial fibrillation technologies, today ... by the US Patent and Trademark Office (USPTO), ... profile electrode assemblies for use on expandable structures ... other surgical procedures. "We are grateful ...

Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2 One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6

[0] One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs [0] Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics [0] Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons

... EVEN MORE SCIENCE SUPPORTING THE, THEORY THAT ... Mo., May 19 A primate model for ... at the,International Meeting For Autism Research (IMFAR) this ... into vaccine safety and,the immune and mitochondrial dysfunction ...

... Native Bladder by Six Months; Data Presented at May 18 Press ... ... ORLANDO, Fla. and EAST NORRITON, Pa., May 19 Tengion,Inc., a ... presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at the Annual ...

Cached Medicine Technology:UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2 Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2

UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....

For the quantitative determination of iron, total iron-binding capacity in human serum....

HDL Cholesterol, liquid....

Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...

Medicine Products:

Iron / TIBC (Ferrozine)Iron/TIBC Reagent Set HDL Cholesterol (Precipitation)HDL-Cholesterol Direct Reagent